RLMD net incomeQ2 2026-$12.91M
RLMD net income was -$12.91M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.87M a year earlier. For the full fiscal 2025 it was -$57.39M, compared with -$79.98M in fiscal 2024.
Relmada Therapeutics Inc. (RLMD) financials
For the twelve months ended Jun 30, 2026, Relmada Therapeutics Inc. reported -$61.93M of net income.
- Net income, TTM
- -$61.93M
- Cash
- $11.33M
- Market cap
- $441.6M
FY2016FY2025
FY2016FY2020
RLMD revenue and earnings growth
RLMD EPSQ2 2026-$0.11
RLMD diluted EPS was -$0.11 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.45, compared with -$2.65 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $26.88M | $46.18M | $54.81M | $113.32M | $90.62M | $35.97M | $7.86M | $2.94M | $1.29M | $6.21M |
| Selling, general and admin | $32.22M | $37.72M | $48.89M | $47.93M | $35.08M | $24.87M | $7.25M | $3.97M | $5.93M | $10.01M |
| Operating income | -$59.10M | -$83.89M | -$103.70M | -$161.25M | -$125.70M | -$60.84M | -$15.11M | -$6.92M | -$7.22M | -$16.22M |
| Net income | -$57.39M | -$79.98M | -$98.79M | -$157.04M | -$125.75M | -$59.46M | -$15.01M | -$8.96M | -$6.29M | -$2.97M |
| EPS, basic | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.86 | -$2.08 | -$1.04 |
| EPS, diluted | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | -$3.81 | -$1.62 | -$2.86 | -$2.08 | -$1.04 |
| Diluted shares | 39.5M | 30.2M | 30.1M | 29.6M | 17.6M | 15.6M | 9.2M | 3.1M | 3.0M | 2.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.50M | $3.86M | $4.09M | $5.40M | $44.44M | $2.50M | $36.28M | $2.24M | $1.71M | $8.50M |
| Short-term investments | $89.51M | $41.05M | $92.23M | $142.93M | $167.47M | $114.60M | $80.16M | - | - | - |
| Receivables | - | - | - | $512.4K | - | - | - | - | - | - |
| Current assets | $93.98M | $45.80M | $97.51M | $152.87M | $223.30M | $118.07M | $116.94M | $2.74M | $2.47M | $9.30M |
| Total assets | $94.00M | $45.82M | $97.55M | $152.91M | $223.33M | $118.19M | $117.14M | $3.05M | $2.84M | $10.24M |
| Current liabilities | $6.43M | $10.29M | $12.19M | $12.47M | $15.06M | $12.60M | $1.46M | $5.90M | $1.38M | $3.06M |
| Total debt | - | - | - | - | - | $0 | $110.2K | $285.2K | $276.7K | $273.7K |
| Total liabilities | $7.49M | $10.30M | $12.19M | $12.47M | $15.06M | $12.60M | $1.46M | $8.56M | $1.38M | $3.20M |
| Shareholders' equity | $86.51M | $35.52M | $85.36M | $140.44M | $208.26M | $105.58M | $115.68M | -$5.51M | $1.46M | $7.04M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.79M | -$51.76M | -$51.66M | -$103.80M | -$91.87M | -$27.81M | -$12.09M | -$6.00M | -$6.47M | -$13.14M |
| Capital expenditures | - | - | - | - | - | $182.05M | $84.85M | $12.4K | $49.7K | $562.3K |
| Free cash flow | - | - | - | - | - | -$209.86M | -$96.94M | -$6.01M | -$6.52M | -$13.71M |
| Investing cash flow | -$48.14M | $51.56M | $50.45M | $19.73M | -$54.12M | -$34.45M | -$80.16M | -$12.4K | -$49.7K | -$562.3K |
| Financing cash flow | $93.56M | -$40.3K | -$98.5K | $45.02M | $187.94M | $28.47M | $126.11M | $6.54M | -$273.7K | -$263.8K |
| Stock-based compensation | $13.91M | $30.18M | $43.81M | $44.19M | $40.49M | $20.78M | $3.17M | $518.0K | $704.5K | $1.00M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -66.3% | -225.2% | -115.7% | -111.8% | -60.4% | -56.3% | -13.0% | - | -430.5% | -42.2% |
| Return on assets | -61.0% | -174.6% | -101.3% | -102.7% | -56.3% | -50.3% | -12.8% | -294.0% | -221.6% | -29.0% |
| Current ratio | 14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.21 | 0.46 | 1.80 | 3.04 |
| Debt to equity | - | - | - | - | - | 0.00 | 0.00 | - | 0.19 | 0.04 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $8.39M | $8.09M | $8.07M | $4.04M | $2.82M | $11.95M | $11.00M | $11.15M | $10.72M | $13.31M | $14.75M | $10.45M |
| Selling, general and admin | $6.62M | $11.37M | $12.26M | $6.29M | $7.40M | $6.27M | $8.08M | $11.86M | $8.10M | $9.68M | $12.08M | $12.24M |
| Operating income | -$15.01M | -$19.46M | -$20.33M | -$10.33M | -$10.22M | -$18.22M | -$19.08M | -$23.01M | -$18.82M | -$22.99M | -$26.83M | -$22.69M |
| Net income | -$12.91M | -$19.05M | -$19.87M | -$10.09M | -$9.87M | -$17.56M | -$18.66M | -$21.73M | -$17.77M | -$21.83M | -$25.17M | -$22.00M |
| EPS, basic | -$0.11 | -$0.22 | - | -$0.30 | -$0.30 | -$0.58 | -$0.62 | -$0.72 | -$0.59 | -$0.72 | -$0.84 | -$0.73 |
| EPS, diluted | -$0.11 | -$0.22 | - | -$0.30 | -$0.30 | -$0.58 | -$0.62 | -$0.72 | -$0.59 | -$0.72 | -$0.84 | -$0.73 |
| Diluted shares | 112.4M | 86.6M | - | 33.2M | 33.2M | 30.4M | - | 30.2M | 30.2M | 30.1M | - | 30.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.33M | $9.78M | $3.50M | $1.38M | $1.35M | $1.15M | $3.86M | $1.48M | $2.09M | $1.34M | $4.09M | $6.70M |
| Short-term investments | $206.40M | $224.19M | $89.51M | $12.50M | $19.27M | $25.91M | $41.05M | $52.63M | $68.35M | $82.28M | $92.23M | $99.57M |
| Current assets | $219.04M | $235.34M | $93.98M | $14.85M | $21.09M | $27.66M | $45.80M | $55.70M | $70.97M | $84.37M | $97.51M | $109.10M |
| Total assets | $219.06M | $235.36M | $94.00M | $14.88M | $21.12M | $27.68M | $45.82M | $55.72M | $71.03M | $84.41M | $97.55M | $109.15M |
| Current liabilities | $7.42M | $12.89M | $6.43M | $5.19M | $5.13M | $5.23M | $10.29M | $8.09M | $9.54M | $12.36M | $12.19M | $8.42M |
| Total liabilities | $12.50M | $16.63M | $7.49M | $5.41M | $5.17M | $5.24M | $10.30M | $8.10M | - | $12.36M | $12.19M | - |
| Shareholders' equity | $206.56M | $218.73M | $86.51M | $9.47M | $15.95M | $22.44M | $35.52M | $47.63M | $61.49M | $72.05M | $85.36M | $100.73M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.61M | -$15.07M | -$14.60M | -$6.72M | -$6.40M | -$18.07M | -$8.80M | -$16.66M | -$13.26M | -$13.04M | -$10.25M | -$11.63M |
| Investing cash flow | $17.59M | -$135.23M | -$76.93M | $6.75M | $6.68M | $15.36M | $11.35M | $16.14M | $14.01M | $10.06M | $7.74M | $3.86M |
| Financing cash flow | -$6.42M | $156.57M | $93.64M | $0 | - | - | -$172.5K | -$89.6K | $0 | $221.7K | - | - |
| Share repurchases | $6.46M | $3.36M | - | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | $902.9K | $956.2K | $2.37M | $4.51M | $3.45M | $3.57M | $6.73M | $7.95M | $7.21M | $8.30M | $9.89M | $11.39M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 29.52 | 18.26 | 14.62 | 2.86 | 4.11 | 5.29 | 4.45 | 6.89 | 7.44 | 6.82 | 8.00 | 12.95 |
Source: XBRL data Relmada Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-5, first reported Sep 11, 2015; 1-for-4, first reported Nov 13, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RLMD peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RLMD | - | - | -$61.93M | - | $441.6M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
RLMD FAQ
4 questionsIs RLMD profitable?
No. Relmada Therapeutics Inc. reported a net loss of $61.93M for the twelve months ended Jun 30, 2026.How much cash and debt does RLMD have?
Relmada Therapeutics Inc. reported $11.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did RLMD last report financial results?
The latest statements here come from Relmada Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.Where does this RLMD financial data come from?
Quantisnow builds these statements from the structured XBRL data Relmada Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.